Monitoring treatment response in patients affected by actinic keratosis: Dermoscopic assessment and metalloproteinases evaluation after piroxicam 0.8% and sunfilter cream

Dermatol Ther. 2019 Jan;32(1):e12772. doi: 10.1111/dth.12772. Epub 2018 Nov 4.

Authors

Laura Diluvio¹, Mauro Bavetta¹, Gaetana Costanza², Augusto Orlandi², Luca Bianchi¹, Elena Campione¹

Affiliations

¹ Department of Systems Medicine, Division of Dermatology, University of Rome "Tor Vergata", Rome, Italy.
² Department of Biomedicine and Prevention, Division of Anatomic Pathology, University of Rome "Tor Vergata", Rome, Italy.

PMID: 30318747
DOI: 10.1111/dth.12772

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Aged
Biopsy
Cyclooxygenase Inhibitors / administration & dosage*
Cyclooxygenase Inhibitors / adverse effects
Dermoscopy*
Female
Humans
Immunohistochemistry
Keratosis, Actinic / diagnosis
Keratosis, Actinic / drug therapy*
Keratosis, Actinic / enzymology
Male
Matrix Metalloproteinase 1 / metabolism*
Matrix Metalloproteinase 2 / metabolism*
Middle Aged
Piroxicam / administration & dosage*
Piroxicam / adverse effects
Predictive Value of Tests
Skin / drug effects*
Skin / enzymology
Skin / pathology
Sunscreening Agents / administration & dosage*
Sunscreening Agents / adverse effects
Time Factors
Treatment Outcome

Substances

Cyclooxygenase Inhibitors
Sunscreening Agents
Piroxicam
MMP2 protein, human
Matrix Metalloproteinase 2
MMP1 protein, human
Matrix Metalloproteinase 1